• Skip to main navigation
  • Skip to main content
  • Skip to footer
Theranostics

Theranostics

University Health Network

  • Home
  • Theranostics Members
    • Researchers
    • Departments
    • Resources
    • Working Group Members
  • Publications
  • Clinical Trials
  • Contact Us
  • Skip to menu toggle button

Month: March 2021

Hello world!

Posted on: 12 March 2021 Last updated on: 12 March 2021 Written by: admtechna
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Continue reading “Hello world!”…

Recent Posts

Prostate-specific antigen density does not predict metastatic disease on PSMA-PET in high-risk prostate cancer patients with negative conventional imaging

Can Urol Assoc J. 2025 Sep;19(9):E307-E311. doi: 10.5489/cuaj.9113. ABSTRACT INTRODUCTION: The ability of prostate-specific antigen density (PSAD) to predict metastatic disease on prostate-specific membrane antigen-positron emission tomography (PSMA-PET) at initial staging in high-risk prostate cancer (PCa) for men with negative…
Continue reading “Prostate-specific antigen density does not predict metastatic disease on PSMA-PET in high-risk prostate cancer patients with negative conventional imaging”…

Targeted Radionuclide Therapy Using a Lutetium-177 Labeled Human Anti-CD133 Antibody

Mol Imaging Biol. 2025 Aug;27(4):606-616. doi: 10.1007/s11307-025-02013-4. Epub 2025 May 22. ABSTRACT PURPOSE: Targeted radionuclide therapy against cancer stem cell-specific markers, such as CD133, constitutes a promising strategy to eliminate resilient cancer stem cells for improved outcomes in refractory tumors.…
Continue reading “Targeted Radionuclide Therapy Using a Lutetium-177 Labeled Human Anti-CD133 Antibody”…

PSMA PET-detected mesorectal nodal metastasis: treatment outcomes and clinical implications

World J Urol. 2025 Jun 3;43(1):352. doi: 10.1007/s00345-025-05733-y. ABSTRACT PURPOSE: To evaluate the clinical significance of PSMA-PET/CT-detected mesorectal lymph node metastases in biochemically recurrent prostate cancer patients. METHODS: This is a retrospective analysis of biochemically recurrent prostate cancer patients (post-radical…
Continue reading “PSMA PET-detected mesorectal nodal metastasis: treatment outcomes and clinical implications”…

Convection-enhanced delivery of [177Lu]Lu-labeled gold nanoparticles combined with anti-PD1 checkpoint immunotherapy improves the survival of immunocompetent C57BL/6J mice with orthotopic GL261 murine glioma tumors

Nucl Med Biol. 2025 Jan-Feb;140-141:108970. doi: 10.1016/j.nucmedbio.2024.108970. Epub 2024 Nov 9. ABSTRACT INTRODUCTION: Our objective was to study convection enhanced delivery (CED) of 177Lu-labeled metal chelating polymer (MCP) conjugated to gold nanoparticles ([177Lu]Lu-MCP-AuNP) alone or combined with anti-PD1 immune checkpoint…
Continue reading “Convection-enhanced delivery of [177Lu]Lu-labeled gold nanoparticles combined with anti-PD1 checkpoint immunotherapy improves the survival of immunocompetent C57BL/6J mice with orthotopic GL261 murine glioma tumors”…

18 F-DCFPyL in the Detection of Prostate Cancer Spread to the Lumbosacral Plexus

Clin Nucl Med. 2025 Apr 1;50(4):e232-e233. doi: 10.1097/RLU.0000000000005472. Epub 2024 Dec 13. ABSTRACT In most cases, prostate cancer spreads locally to the seminal vesicles, via lymphatics to pelvic and abdominal lymph nodes, and hematogenously to the bones. Direct invasion along…
Continue reading “18 F-DCFPyL in the Detection of Prostate Cancer Spread to the Lumbosacral Plexus”…

Recent Comments

  • A WordPress Commenter on Hello world!

Archives

  • September 2025
  • June 2025
  • March 2025
  • November 2024
  • March 2024
  • December 2023
  • November 2023
  • September 2023
  • May 2023
  • February 2023
  • October 2022
  • August 2022
  • March 2021

Categories

  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • Home
  • Theranostics Members
  • Publications
  • Clinical Trials
  • Contact Us
© 2025 Theranostics | Using Icelander WordPress theme. | Privacy and Cookie Policy | Back to top ↑
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.